Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Neurocrine Biosciences stock

Own Neurocrine Biosciences stock in just a few minutes.

Posted

Fact checked

Neurocrine Biosciences, Inc is a biotechnology business based in the US. Neurocrine Biosciences shares (NBIX) are listed on the NASDAQ and all prices are listed in US Dollars. Neurocrine Biosciences employs 845 staff and has a trailing 12-month revenue of around USD$1 billion.

How to buy shares in Neurocrine Biosciences

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Neurocrine Biosciences. Find the stock by name or ticker symbol: NBIX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Neurocrine Biosciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Neurocrine Biosciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Neurocrine Biosciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Neurocrine Biosciences share price

Use our graph to track the performance of NBIX stocks over time.

Neurocrine Biosciences shares at a glance

Information last updated 2021-02-23.
52-week rangeUSD$72.14 - USD$136.2618
50-day moving average USD$111.2582
200-day moving average USD$103.494
Wall St. target priceUSD$129
PE ratio 25.8606
Dividend yield N/A (0%)
Earnings per share (TTM) USD$4.16

Buy Neurocrine Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Neurocrine Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Neurocrine Biosciences under- or over-valued?

Valuing Neurocrine Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Neurocrine Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Neurocrine Biosciences's P/E ratio

Neurocrine Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 26x. In other words, Neurocrine Biosciences shares trade at around 26x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Neurocrine Biosciences's PEG ratio

Neurocrine Biosciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.87. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Neurocrine Biosciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Neurocrine Biosciences's EBITDA

Neurocrine Biosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$336.1 million.

The EBITDA is a measure of a Neurocrine Biosciences's overall financial performance and is widely used to measure a its profitability.

Neurocrine Biosciences financials

Revenue TTM USD$1 billion
Operating margin TTM 31.31%
Gross profit TTM USD$760.8 million
Return on assets TTM 13.46%
Return on equity TTM 46.2%
Profit margin 38.94%
Book value $12.045
Market capitalisation USD$10.1 billion

TTM: trailing 12 months

Shorting Neurocrine Biosciences shares

There are currently 4.1 million Neurocrine Biosciences shares held short by investors – that's known as Neurocrine Biosciences's "short interest". This figure is 6.3% down from 4.4 million last month.

There are a few different ways that this level of interest in shorting Neurocrine Biosciences shares can be evaluated.

Neurocrine Biosciences's "short interest ratio" (SIR)

Neurocrine Biosciences's "short interest ratio" (SIR) is the quantity of Neurocrine Biosciences shares currently shorted divided by the average quantity of Neurocrine Biosciences shares traded daily (recently around 910303.55555556). Neurocrine Biosciences's SIR currently stands at 4.5. In other words for every 100,000 Neurocrine Biosciences shares traded daily on the market, roughly 4500 shares are currently held short.

However Neurocrine Biosciences's short interest can also be evaluated against the total number of Neurocrine Biosciences shares, or, against the total number of tradable Neurocrine Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Neurocrine Biosciences's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Neurocrine Biosciences shares in existence, roughly 40 shares are currently held short) or 0.0442% of the tradable shares (for every 100,000 tradable Neurocrine Biosciences shares, roughly 44 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Neurocrine Biosciences.

Find out more about how you can short Neurocrine Biosciences stock.

Neurocrine Biosciences share dividends

We're not expecting Neurocrine Biosciences to pay a dividend over the next 12 months.

Neurocrine Biosciences share price volatility

Over the last 12 months, Neurocrine Biosciences's shares have ranged in value from as little as $72.14 up to $136.2618. A popular way to gauge a stock's volatility is its "beta".

NBIX.US volatility(beta: 0.84)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neurocrine Biosciences's is 0.8394. This would suggest that Neurocrine Biosciences's shares are less volatile than average (for this exchange).

Neurocrine Biosciences overview

Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients with SCN8A-DEE, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for the treatment of rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for the treatment of anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL ? Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site